Zobrazeno 1 - 10
of 16
pro vyhledávání: '"J D, Ellenhorn"'
Autor:
W M Kast, J A Bluestone, M H Heemskerk, J Spaargaren, A C Voordouw, J D Ellenhorn, C J Melief
Publikováno v:
The Journal of Immunology. 145:2254-2259
C57BL/6 mice are protected from a lethal pneumonia caused by Sendai virus when treated with low doses of mAb directed to the CD3 Ag. The protective mechanism is not due to an accelerated Sendai virus-specific Th cell, CTL, or antibody response but to
Publikováno v:
The Journal of Immunology. 144:2840-2846
The present study was undertaken to determine the mechanism of tumor rejection in mice treated with low dose anti-CD3 mAb. It was found that treated mice developed nonrestricted antitumor cytolytic spleen cells of the Thy-1+, asialo GM-1+, CD4-, CD8-
Publikováno v:
The American surgeon. 67(12)
Although cancers of the rectum and kidney are common malignancies the incidence of coexistent rectal and renal primary tumors is unclear. Our objective was to determine the true incidence of synchronous neoplasms of the rectum and kidney. The compute
Autor:
S, Blair, J D, Ellenhorn
Publikováno v:
The American surgeon. 66(9)
Controversy still exists as to the optimal treatment of early-stage low rectal cancers. Standard resections such as abdominal perineal resections or low anterior resection with coloanal anastomosis can be associated with significant morbidity. Local
Publikováno v:
Journal of the American College of Surgeons. 190(3)
Because inflammatory breast cancer (IBC) has been viewed as a malignancy with a poor likelihood of longterm survival, few women have been offered esthetic reconstruction after mastectomy for IBC. Recent advances in multimodality therapy have improved
Publikováno v:
Cancer research. 60(3)
A potent anti-human (hu) p53 CD8+ CTL response develops in HLA A*0201 transgenic (Tg) mice after immunization with peptides corresponding to HLA A*0201 motifs from hu p53. Mice immunized with the hu P53(149-157) peptide develop a CTL response that is
Publikováno v:
The Journal of urology. 162(5)
Superficial bladder cancer is often responsive to immunotherapy with bacillus Calmette-Guerin (BCG). However, some tumors progress despite BCG treatment, and most of these have mutations in the p53 tumor suppressor gene resulting in its over-expressi
Publikováno v:
The American surgeon. 65(10)
Pancreatoduodenectomy (PD) for periampullary cancer is a procedure of high morbidity and poor long-term survival. Superior clinical outcome has been described in high-volume institutions or for surgeons with a high case load. All patients undergoing
Publikováno v:
Surgery. 126(3)
Pancreatic cancer is a highly lethal disease that frequently presents in advanced stages. For most patients, treatment with great clinical efficacy does not exist. Relevant in vivo models to test novel therapies are highly desirable.The human pancrea
Publikováno v:
Cancer research. 58(12)
p53 gene mutations occur in most human cancers and result in an altered protein product that accumulates within the cell. Although the observed endogenous human CTL response to p53 is weak, high-affinity, human p53-specific CTLs have been generated f